{
  "items": "28",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Allurion Shareholders Approve Governance Changes and Capital Actions",
      "url": "https://www.tipranks.com/news/company-announcements/allurion-shareholders-approve-governance-changes-and-capital-actions",
      "time_published": "20251219T220929",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Allurion Technologies shareholders have re-elected directors, ratified Deloitte & Touche LLP as auditor, and approved several significant governance changes and capital actions at their annual meeting on December 18, 2025. These include amending their stock option plan, authorizing common share issuances, and approving a reverse stock split. These moves aim to enhance capital structure flexibility, ensure NYSE listing compliance, and support the company's governance framework.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1423187486-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.902641"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.829045"
        },
        {
          "topic": "finance",
          "relevance_score": "0.713787"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.922507"
        },
        {
          "topic": "technology",
          "relevance_score": "0.605961"
        }
      ],
      "overall_sentiment_score": 0.031147,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.032694",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session",
      "url": "https://www.benzinga.com/insights/movers/25/12/49180489/12-consumer-discretionary-stocks-moving-in-wednesdays-pre-market-session",
      "time_published": "20251204T052111",
      "authors": [
        "Benzinga Insights",
        "Benzinga Staff Writer"
      ],
      "summary": "This article details the pre-market movements of 12 Consumer Discretionary stocks on a Wednesday, identifying both gainers and losers. American Eagle Outfitters, Massimo, Tilly's, Nerdy, Vestand, and Fitell saw their shares rise, often driven by recent earnings reports. Conversely, Lulus Fashion Lounge, Leslies, Allurion Technologies, Boqii Holding, Twin Vee PowerCats, and Fly-E Group experienced declines.",
      "banner_image": "https://cdn.benzinga.com/files/images/story/2025/07/24/article-header-background-image.png?quality=85&auto=webp&width=1300",
      "source": "Benzinga",
      "category_within_source": "General",
      "source_domain": "Benzinga",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.942333"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.808715"
        },
        {
          "topic": "retail_wholesale",
          "relevance_score": "0.723159"
        }
      ],
      "overall_sentiment_score": 0.049265,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "0.341908",
          "ticker_sentiment_score": "0.016162",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Allurion (NYSE: ALUR) Reports 20% Weight Loss, Better Body Composition at 36 Weeks",
      "url": "https://www.stocktitan.net/news/ALUR/new-peer-reviewed-publication-demonstrates-superior-weight-loss-and-zms9aeyd48at.html",
      "time_published": "20251127T190928",
      "authors": [
        "NULL"
      ],
      "summary": "Allurion Technologies announced a peer-reviewed study showing that their Smart Capsule, combined with lifestyle intervention, leads to significant weight loss and improved body composition. Patients achieved an average 20% weight reduction at 36 weeks, surpassing results from lifestyle intervention alone and demonstrating comparable efficacy to bariatric surgery and high-dose GLP-1 therapy with a better safety profile. This data strengthens the evidence for the Allurion Smart Capsule as a valuable obesity management tool.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.919543"
        }
      ],
      "overall_sentiment_score": 0.458264,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.451854",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion (NYSE: ALUR) Posts 23% Weight Loss, 14% Lean Mass Gain With Low-Dose Tirzepatide",
      "url": "https://www.stocktitan.net/news/ALUR/allurion-announces-initial-results-on-combining-the-allurion-program-cd8k7t4lpj3d.html",
      "time_published": "20251126T230932",
      "authors": [
        "NULL"
      ],
      "summary": "Allurion (NYSE: ALUR) announced initial results from combining its Program with low-dose tirzepatide, showing an average of 23% total weight loss and a 14% increase in lean body mass after 12 months in 76 patients. This approach aims to optimize muscle mass and GLP-1 adherence, addressing common challenges of GLP-1 therapies such as muscle wasting and discontinuation due to side effects or cost. The company plans further validation through a prospective clinical trial.",
      "banner_image": "https://cts.businesswire.com/ct/CT?id=bwnews&sty=20251125509141r1&sid=acqr8&distro=nx&lang=en",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.902982"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.818274"
        }
      ],
      "overall_sentiment_score": 0.021159,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "0.321452",
          "ticker_sentiment_score": "0.033311",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence",
      "url": "https://www.biospace.com/press-releases/allurion-announces-initial-results-on-combining-the-allurion-program-with-low-dose-tirzepatide-to-optimize-muscle-mass-and-glp-1-adherence",
      "time_published": "20251126T000849",
      "authors": [
        "NULL"
      ],
      "summary": "Allurion Technologies announced initial results on combining its Program with low-dose tirzepatide to optimize muscle mass and GLP-1 adherence. The study showed an average total body weight loss of 23% and a 14% increase in lean body mass over 12 months, with all patients adhering to the tirzepatide therapy. This combination approach aims to address challenges of muscle wasting and poor adherence often seen with GLP-1s alone, suggesting a new potential standard of care for weight loss.",
      "banner_image": "https://mms.businesswire.com/media/20251125509141/en/1755824/22/Allurion_logo_HD.jpg",
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928180"
        }
      ],
      "overall_sentiment_score": 0.457659,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.453262",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss",
      "url": "https://www.businesswire.com/news/home/20251118611730/en/Allurion-Announces-Strategic-Distribution-Partnership-with-ProSurg-Medical-in-Brazil-to-Pioneer-New-Approach-Focused-on-Metabolically-Healthy-Weight-Loss",
      "time_published": "20251122T220857",
      "authors": [],
      "summary": "Allurion Technologies, Inc. (NYSE: ALUR) has formed a strategic distribution partnership with ProSurg Medical in Brazil to introduce a new approach to obesity care focused on metabolically healthy weight loss. This collaboration aims to leverage ProSurg Medical's extensive experience in the Brazilian market and expand access to the Allurion Program, potentially in combination with GLP-1 therapy. The partnership seeks to establish a new standard of care in obesity management by prioritizing comprehensive patient care and improved clinical outcomes.",
      "banner_image": "https://mms.businesswire.com/media/20251118611730/en/1755824/4/Allurion_logo_HD.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932415"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.846255"
        }
      ],
      "overall_sentiment_score": 0.477724,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.473184",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Chardan Capital Maintains Allurion Technologies (ALUR) Neutral Recommendation",
      "url": "https://www.nasdaq.com/articles/chardan-capital-maintains-allurion-technologies-alur-neutral-recommendation",
      "time_published": "20251120T123600",
      "authors": [
        "George Maybach"
      ],
      "summary": "Chardan Capital research analyst maintains a Neutral recommendation on Allurion Technologies (ALUR). The average one-year price target suggests a 328.06% upside from its latest reported closing price. Institutional ownership in the company has seen a slight decrease in the last quarter, with 26 funds reporting positions.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.919760"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.807932"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.739514"
        }
      ],
      "overall_sentiment_score": 0.292392,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.271238",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Allurion Technologies Delays Q3 2025 Report Filing",
      "url": "https://www.tipranks.com/news/company-announcements/allurion-technologies-delays-q3-2025-report-filing",
      "time_published": "20251117T210911",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Allurion Technologies (ALUR) has announced a delay in filing its Form 10-Q report for Q3 2025 due to the need for additional review time. The company anticipates a significant revenue drop to approximately $2.7 million from $5.4 million in the same period last year. An analyst has rated ALUR stock as a Sell with a $1.50 price target, and TipRanks' AI Analyst, Spark, also rates it as Underperform due to poor financial performance and bearish technical indicators.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2051377127-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.913473"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.837809"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.626587"
        }
      ],
      "overall_sentiment_score": -0.630039,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.621773",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "ALLURION TECHNOLOGIES, INC. SEC 10-Q Report",
      "url": "https://www.tradingview.com/news/tradingview:6e84560410287:0-allurion-technologies-inc-sec-10-q-report/",
      "time_published": "20251117T052111",
      "authors": [
        "NULL"
      ],
      "summary": "Allurion Technologies, Inc. (ALUR) has released its Q3 2025 Form 10-Q report, revealing significant financial and operational challenges, including a decline in revenue to $2.7 million from $5.4 million year-over-year, and a net loss of $(11.9) million. The company faces ongoing operational hurdles, including reliance on third-party suppliers, and anticipates continued net losses, raising substantial doubt about its ability to continue as a going concern. Allurion plans to pursue equity, debt financing, or other capital transactions to fund operations and meet liquidity requirements.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.900098"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.745889"
        },
        {
          "topic": "finance",
          "relevance_score": "0.622582"
        }
      ],
      "overall_sentiment_score": 0.018466,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "0.304563",
          "ticker_sentiment_score": "0.043536",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Allurion Technologies (ALUR) Price Target Decreased by 30.35% to 5.95",
      "url": "https://www.nasdaq.com/articles/allurion-technologies-alur-price-target-decreased-3035-595",
      "time_published": "20251112T230848",
      "authors": [
        "George Maybach"
      ],
      "summary": "The average one-year price target for Allurion Technologies (NYSE: ALUR) has been lowered by 30.35% to $5.95 per share from $8.54. This revised target, an average of multiple analyst estimates, suggests a potential upside of 218.18% from the last closing price of $1.87. Institutional ownership in ALUR has increased significantly, with total shares owned by institutions rising by 101.33% in the last three months.",
      "banner_image": "NULL",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.924918"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.829405"
        },
        {
          "topic": "finance",
          "relevance_score": "0.738807"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.625830"
        }
      ],
      "overall_sentiment_score": -0.261828,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.253804",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update",
      "url": "https://www.businesswire.com/news/home/20251112567975/en/Allurion-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update",
      "time_published": "20251112T163017",
      "authors": [],
      "summary": "Allurion Technologies, Inc. announced its third-quarter 2025 financial results, highlighting significant milestones towards FDA approval and strategic financial restructuring. The company reported reduced operating losses and expenses, alongside a transaction to exchange outstanding debt for convertible preferred equity and a private placement financing of $5 million. CEO Dr. Shantanu Gaur emphasized progress in FDA inspections and the potential for the Allurion Smart Capsule as a platform technology for drug delivery.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.914096"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.844490"
        }
      ],
      "overall_sentiment_score": 0.281417,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.277259",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing",
      "url": "https://www.biospace.com/press-releases/allurion-passes-critical-fda-milestones-enters-into-transaction-to-exchange-all-outstanding-debt-that-would-result-in-the-company-being-debt-free-and-announces-a-5-million-private-placement-financing",
      "time_published": "20251110T052111",
      "authors": [
        "NULL"
      ],
      "summary": "Allurion Technologies, Inc. (NYSE: ALUR) announced significant progress in the FDA Pre-Market Approval process for its Allurion Smart Capsule, including passing critical inspections with zero findings and completing its Day-100 Meeting. The company also entered a transaction to exchange all outstanding debt for convertible preferred stock, aiming to become debt-free, and secured a $5 million private placement financing to strengthen its financial position. These moves are strategic as Allurion nears potential FDA approval and a U.S. launch for its weight loss solution.",
      "banner_image": "https://mms.businesswire.com/media/20251111733050/en/1755824/22/Allurion_logo_HD.jpg",
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.935784"
        },
        {
          "topic": "finance",
          "relevance_score": "0.805968"
        }
      ],
      "overall_sentiment_score": 0.471015,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.450323",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion Technologies Inc expected to post a loss of $1.97 a share - Earnings Preview",
      "url": "https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3WJ21O:0-allurion-technologies-inc-expected-to-post-a-loss-of-1-97-a-share-earnings-preview/",
      "time_published": "20251110T000849",
      "authors": [
        "Refinitiv"
      ],
      "summary": "Allurion Technologies Inc. (ALUR) is projected to report a loss of $1.97 per share and a 60.3% decrease in quarterly revenue for the period ending September 30, 2025, according to analyst estimates. The company's revenue is expected to be $2.133 million, down from $5.37 million a year ago. Analysts have a \"buy\" rating on the stock with a median 12-month price target of $6.00.",
      "banner_image": "NULL",
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.901933"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.739332"
        }
      ],
      "overall_sentiment_score": -0.248377,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.201879",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025",
      "url": "https://www.businesswire.com/news/home/20251106241021/en/Allurion-to-Report-Third-Quarter-2025-Financial-Results-on-November-12-2025",
      "time_published": "20251108T052110",
      "authors": [
        "NULL"
      ],
      "summary": "Allurion Technologies, Inc. (NYSE: ALUR) announced it will report its third-quarter 2025 financial results on Wednesday, November 12, 2025. The company will host a conference call on the same day at 8:30 AM ET to discuss these results and provide a business update. Investors can access the call via telephone or live audio webcast through Allurion\u2019s Investor Relations website.",
      "banner_image": "https://mms.businesswire.com/media/20251106241021/en/1755824/4/Allurion_logo_HD.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.830953"
        }
      ],
      "overall_sentiment_score": 0.106673,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.123638",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss",
      "url": "https://www.businesswire.com/news/home/20251007124643/en/Allurion-Announces-Landmark-Peer-Reviewed-Publication-on-Consecutive-Use-of-the-Allurion-Smart-Capsule-Showing-More-Than-20-Weight-Loss",
      "time_published": "20251007T000000",
      "authors": [],
      "summary": "Allurion Technologies announced a landmark peer-reviewed publication demonstrating that consecutive use of their Smart Capsule leads to over 20% weight loss, comparable to bariatric surgery and high-dose GLP-1 therapy. The multicenter study found the treatment to be safe and effective for adults with obesity, broadening non-surgical weight loss options. This research reinforces the potential of the Allurion Smart Capsule as a first-line therapy and supports the company's FDA Pre-Market Approval application.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910315"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.643866"
        }
      ],
      "overall_sentiment_score": 0.824563,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.803058",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry",
      "url": "https://www.biospace.com/press-releases/allurion-announces-new-strategic-direction-with-increasing-focus-on-low-dose-glp-1-combination-therapy-muscle-mass-maintenance-and-us-market-entry",
      "time_published": "20250805T090000",
      "authors": [],
      "summary": "Allurion Technologies, Inc. has unveiled a new strategic direction, emphasizing low-dose GLP-1 combination therapy, muscle mass maintenance, and entry into the US market. The company has signed a term sheet with a strategic partner for expanded distribution and R&D, including a potential GLP-1 drug-eluting balloon, and has submitted protocols for a multi-center trial on combination therapy. This pivot is expected to establish a new standard of obesity care, resulting in an estimated preliminary Q2 2025 revenue of approximately $3 million and an operating loss of approximately $7 million.",
      "banner_image": null,
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913619"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.710146"
        }
      ],
      "overall_sentiment_score": 0.469894,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.472344",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss",
      "url": "https://finance.yahoo.com/news/allurion-announces-strategic-distribution-partnership-200500999.html",
      "time_published": "20250709T200500",
      "authors": [],
      "summary": "Allurion Technologies, Inc. has announced a strategic distribution partnership with Minogue Medical Inc. in Canada to focus on metabolically healthy weight loss. This collaboration aims to leverage Minogue Medical's extensive experience and network to establish a new standard of care in obesity management in the Canadian market, including increasing access to Allurion's Program combined with GLP-1 therapy. The partnership emphasizes ethical, patient-centered care and rigorous clinical practice.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.914780"
        }
      ],
      "overall_sentiment_score": 0.472142,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.498567",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion Technologies Inc. (ALUR) reports earnings",
      "url": "https://qz.com/allurion-technologies-inc-alur-reports-earnings-1851772948",
      "time_published": "20250327T000000",
      "authors": [
        "Quartz Intelligence Newsroom"
      ],
      "summary": "Allurion Technologies Inc. (ALUR) reported a decrease in revenue to $32.1 million for the fiscal year ended December 31, 2024, down from $53.5 million the previous year, attributing the decline to lower re-order rates and macroeconomic challenges. Despite the revenue drop, the company reduced its net loss to $26.1 million from $80.6 million due to significant cuts in operating expenses. Allurion is focusing on new market approvals, product enhancements, and recently resumed sales in France, while also addressing material weaknesses in internal financial controls.",
      "banner_image": null,
      "source": "qz.com",
      "category_within_source": "General",
      "source_domain": "qz.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.927687"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.719445"
        }
      ],
      "overall_sentiment_score": -0.281664,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.263101",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Allurion Technologies\u2019 Unexpected Rise: What\u2019s Next?",
      "url": "https://stockstotrade.com/news/allurion-technologies-inc-alur-news-2025_03_21/",
      "time_published": "20250321T100500",
      "authors": [
        "Tim Bohen"
      ],
      "summary": "Allurion Technologies Inc. has seen a significant stock surge of 52.19% due to recent positive developments, including new partnerships, impressive trial results for its GLP-1 combination with the Allurion Balloon, and new U.S. patents. Despite challenging financial metrics like negative gross margins, the company maintains a comfortable cash position and optimistic financial forecasts from analysts. Its innovative approach to obesity treatment, especially the swallowable gastric balloon combined with digital care, and ongoing research are key drivers of investor interest and future growth prospects.",
      "banner_image": "NULL",
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.935810"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.830183"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.706472"
        },
        {
          "topic": "finance",
          "relevance_score": "0.606955"
        }
      ],
      "overall_sentiment_score": 0.460591,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.486583",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline",
      "url": "https://www.businesswire.com/news/home/20250220313655/en/Allurion-Announces-Closing-of-Offering-and-Concurrent-Private-Placement-to-Advance-GLP-1-Clinical-Pipeline",
      "time_published": "20250220T000000",
      "authors": [],
      "summary": "Allurion Technologies, Inc. announced the closing of a registered direct offering and a concurrent private placement, raising approximately $6.1 million. The funds will be used to advance their clinical pipeline, specifically testing the effects of combined Allurion Balloon and GLP-1 therapy on muscle mass and long-term GLP-1 adherence. Roth Capital Partners acted as the exclusive placement agent for these transactions.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.916339"
        },
        {
          "topic": "finance",
          "relevance_score": "0.843452"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.943393"
        }
      ],
      "overall_sentiment_score": 0.443926,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.400558",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion cleared to resume sale of swallowable gastric balloon in France",
      "url": "https://www.bioworld.com/articles/716939-allurion-cleared-to-resume-sale-of-swallowable-gastric-balloon-in-france",
      "time_published": "20250214T000000",
      "authors": [
        "Shani Alexander"
      ],
      "summary": "Allurion Technologies Inc. has received regulatory clearance in France to resume sales of its swallowable gastric balloon for obesity treatment. The company had previously withdrawn the Allurion Balloon from the French market due to safety concerns. This approval is significant for Allurion, as France represents a substantial part of its market.",
      "banner_image": null,
      "source": "BioWorld MedTech",
      "category_within_source": "General",
      "source_domain": "BioWorld MedTech",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923289"
        }
      ],
      "overall_sentiment_score": 0.498205,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.489265",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "ALUR Stock Price and Chart \u2014 NYSE:ALUR",
      "url": "https://www.tradingview.com/symbols/NYSE-ALUR/",
      "time_published": "20241231T235959",
      "authors": [],
      "summary": "This article provides a detailed overview of Allurion Technologies, Inc. (ALUR) stock performance, key financials, and company information. It includes current stock price, historical price changes, market capitalization, revenue, net income, and employee data. The company's business model focusing on obesity treatments with the Allurion Program is also described.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.927038"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.948736"
        }
      ],
      "overall_sentiment_score": -0.360762,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.358766",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Take Care Before Jumping Onto Allurion Technologies Inc. (NYSE:ALUR) Even Though It's 42% Cheaper",
      "url": "https://simplywall.st/stocks/us/consumer-services/nyse-alur/allurion-technologies/news/take-care-before-jumping-onto-allurion-technologies-inc-nyse",
      "time_published": "20241115T000000",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Allurion Technologies Inc. (NYSE:ALUR) has seen a significant 42% share price drop in the last month, contributing to a 91% decline over the past year. Despite a seemingly low price-to-sales (P/S) ratio of 0.7x compared to the industry average, the company's declining revenue and limited growth forecasts suggest potential risks. Investors are cautioned to investigate further as the low P/S might reflect underlying issues and market skepticism regarding future performance.",
      "banner_image": null,
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.745414"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.913735"
        }
      ],
      "overall_sentiment_score": -0.44027,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.440430",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "October's 4 Best Penny Stocks: High-Risk, High-Reward Picks",
      "url": "https://www.theglobeandmail.com/investing/markets/stocks/ALUR/pressreleases/28897085/octobers-4-best-penny-stocks-high-risk-high-reward-picks/",
      "time_published": "20241004T000000",
      "authors": [
        "Nathan Reiff"
      ],
      "summary": "This article identifies four penny stocks for October 2024, highlighting their high-risk, high-reward nature. Each company\u2014Allurion Technologies (ALUR), Lucid Diagnostics (LUCD), KULR Technology Group (KULR), and Gevo (GEVO)\u2014is presented with its fundamental strengths and growth potential across various industries like weight loss, medical diagnostics, green energy, and renewable fuels. The piece also cautions investors about the inherent volatility and risks associated with penny stocks.",
      "banner_image": null,
      "source": "The Globe and Mail",
      "category_within_source": "General",
      "source_domain": "The Globe and Mail",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.906343"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.733484"
        },
        {
          "topic": "energy_transportation",
          "relevance_score": "0.730092"
        },
        {
          "topic": "technology",
          "relevance_score": "0.609498"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.633220"
        }
      ],
      "overall_sentiment_score": 0.490578,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "0.977618",
          "ticker_sentiment_score": "0.479626",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion Appoints Adrian Wild as Senior Vice President, International Commercial",
      "url": "https://www.citybiz.co/article/591289/allurion-appoints-adrian-wild-as-senior-vice-president-international-commercial/",
      "time_published": "20240820T000000",
      "authors": [],
      "summary": "Allurion Technologies, Inc. has appointed Adrian Wild as its new Senior Vice President, International Commercial, effective August 13, 2024. Mr. Wild will be responsible for leading the company's international commercial sales and operations, bringing extensive experience from leadership roles at Align Technology, Straumann Group, and M\u00f6lnlycke Health Care. This appointment is expected to bolster Allurion's growth as the obesity market expands.",
      "banner_image": null,
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.917404"
        },
        {
          "topic": "finance",
          "relevance_score": "0.639424"
        }
      ],
      "overall_sentiment_score": 0.478351,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.456370",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Allurion, a Global Leader in Weight Loss Technology, to Become Publicly Listed Through Business Combination With Compute Health Acquisition Corp.",
      "url": "https://www.businesswire.com/news/home/20230209005195/en/Allurion-a-Global-Leader-in-Weight-Loss-Technology-to-Become-Publicly-Listed-Through-Business-Combination-With-Compute-Health-Acquisition-Corp.",
      "time_published": "20231231T235959",
      "authors": [],
      "summary": "Allurion Technologies, a company focused on ending obesity, announced a definitive business combination agreement with Compute Health Acquisition Corp. This will result in Allurion becoming a publicly listed company on the NYSE under the symbol \"ALUR.\" The transaction includes significant investments from RTW Investments and others, and is expected to fund the combined company to profitability.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.919116"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.931285"
        }
      ],
      "overall_sentiment_score": 0.031681,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "0.333886",
          "ticker_sentiment_score": "0.010281",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Allurion Announces Appointment of MIT Distinguished Professor for AI and Health and MacArthur \u201cGenius\u201d Fellow Regina Barzilay, Ph.D. to Scientific Advisory Board",
      "url": "https://www.businesswire.com/news/home/20230405005082/en/Allurion-Announces-Appointment-of-MIT-Distinguished-Professor-for-AI-and-Health-and-MacArthur-Genius-Fellow-Regina-Barzilay-Ph.D.-to-Scientific-Advisory-Board",
      "time_published": "20231231T235959",
      "authors": [],
      "summary": "Allurion has appointed Regina Barzilay, Ph.D., a distinguished MIT professor and MacArthur \"Genius\" Fellow, to its Scientific Advisory Board. Dr. Barzilay, an expert in AI and health, will contribute to expanding the use of machine learning and natural language processing in Allurion\u2019s Virtual Care Suite and Iris AI Platform as the company continues to leverage data to improve weight loss outcomes globally.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.945542"
        },
        {
          "topic": "technology",
          "relevance_score": "0.842516"
        }
      ],
      "overall_sentiment_score": 0.423995,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.413081",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Weight loss balloon maker Allurion goes public on NYSE through SPAC merger",
      "url": "https://www.massdevice.com/weight-loss-balloon-allurion-goes-public/",
      "time_published": "20230803T000000",
      "authors": [
        "Sean Whooley"
      ],
      "summary": "Allurion Technologies went public on the NYSE through a SPAC merger with Compute Health Acquisition Corp under the ticker ALUR. The company, known for its swallowable gastric balloon and AI-powered weight loss program, secured approximately $100 million in net proceeds from the merger, exceeding its minimum cash closing condition. Allurion will continue to be led by co-founder and CEO Shantanu Gaur, with former Medtronic CEO Omar Ishrak co-chairing the board.",
      "banner_image": null,
      "source": "MassDevice",
      "category_within_source": "General",
      "source_domain": "MassDevice",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "0.904709"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.881109"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.737983"
        },
        {
          "topic": "technology",
          "relevance_score": "0.642173"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.557077"
        }
      ],
      "overall_sentiment_score": 0.234599,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ALUR",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.479156",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "MDT",
          "relevance_score": "0.617645",
          "ticker_sentiment_score": "0.143336",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.552548",
          "ticker_sentiment_score": "0.136509",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    }
  ]
}